CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A NEW study has explored the effects of combining nivolumab, an immunotherapy drug, with hypofractionated radiotherapy in ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

Findings showed nivolumab/relatlimab did not significantly improve recurrence-free survival compared with nivolumab monotherapy. A phase 3 trial evaluating nivolumab and relatlimab-rmbw (Opdualag ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...